Clinical trials: Pancreas Carcinoma
Metastatic Pancreatic Cancer
Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer
The purpose of this study is to find out if giving patients bevacizumab along with the chemotherapy drugs oxaliplatin and gemcitabine will improve overall survival.
- Trial name
- NCT00222469
- Testing
- bevacizumab, gemcitabine, oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Oklahoma
Solid Tumors, Pancreatic Cancer
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Test the hypothesis that itacitinib (INCB039110) can be administered safely in combination with gemcitabine and nab-paclitaxel in subjects with advanced or metastatic cancer.
- Trial name
- NCT01858883
- Testing
- itacitinib, Gemcitabine, nab-paclitaxel
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- Incyte Corporation
Pancreas Cancer, Pancreatic Cancer
Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
This is a phase 1 open-label study to evaluate the safety and immunogenicity of a neoantigen peptide vaccine strategy in pancreatic cancer patients following surgical resection and adjuvant chemotherapy.
- Conditions
- Pancreas Cancer, Pancreatic Cancer, Cancer of the Pancreas
- Trial name
- NCT03956056
- Testing
- Neoantigen Peptide Vaccine, Poly ICLC, Blood for immune monitoring
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Washington University School of Medicine
Metastatic Pancreatic Cancer
Safety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer
The purpose of the study is to evaluate the efficacy of the combination of gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in patients with metastatic pancreatic cancer.
- Trial name
- GECA (NCT01303029)
- Testing
- Gemcitabine+erlotinib, Gemcitabine+erlotinib+capecitabine
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Recurrent Malignant Solid Neoplasm, Stage IV Breast Cancer
Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites
The study designed is to evaluate the safety of Canady Helios™ Cold Plasma Scalpel (CHCPS) in patients with solid tumors with carcinomatosis scheduled to undergo surgical resection for cytoreduction.
- Conditions
- Recurrent Malignant Solid Neoplasm, Stage IV Breast Cancer, Stage IV Prostate Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT04267575
- Testing
- Canady Helios Cold Plasma Scalpel
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Jerome Canady, M.D.
Metastatic Pancreatic Cancer
A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer
This study is PhaseⅠstudy to examine tolerability and safety of ONO-7475 in combination with ONO-4538 and gemcitabine plus nab-paclitaxel (GnP), the standard of care, and safety of ONO-7475 in combination with GnP in patients…
- Trial name
- NCT06532331
- Testing
- ONO-7475, ONO-4538, Nab-paclitaxel
- Where
- 9 sites in Japan
- Volunteers
- 87 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm
Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with early diagnosis crucial for improving survival. Due to the absence of effective screening methods, most patients are diagnosed at advanced stages.
- Conditions
- Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm, High-grade Pancreatic Intraepithelial Neoplasia, PDAC - Pancreatic Ductal Adenocarcinoma
- Trial name
- AI-LDCT-PC (NCT07117045)
- Testing
- Diagnostic Evaluation for Positive AI Findings
- Where
- 5 sites in China
- Volunteers
- 400,000 people, healthy volunteers welcome
- Sponsor
- Changhai Hospital
Pancreatic Tumor
Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors
Pancreatic cancer is among the most serious human neoplasia and the most difficult to treat. Most patients present at diagnosis a non resectable, locally advanced or metastatic disease, with a median survival of 12 month.
- Trial name
- PACAomics (NCT01692873)
- Testing
- suspected pancreatic tumor
- Where
- France
- Volunteers
- 274 people
- Sponsor
- Institut Paoli-Calmettes
Metastatic Pancreatic Adenocarcinoma
Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer
This study will enroll patients who have metastatic pancreatic cancer and have progressed on prior chemotherapy. Part 1 (dose escalation) participants will receive epacadostat/pembrolizumab/cyclophosphamide(CY)/GVAX pancreas…
- Trial name
- NCT03006302
- Testing
- Epacadostat, Pembrolizumab, CRS-207
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Neoplasms, Inflammation
Dynamic Changes of Sera Immunoglobulin G4 and Interleukin-10 in the Patients of Pancreatic Cancer After Chemotherapy
Investigators have previously found that the infiltration of immunoglobulin G4(IgG4) positive plasma cells in tumor tissue predicts a poor prognosis of pancreatic cancer after curative resection.
- Trial name
- NCT02654288
- Testing
- gemcitabine-based chemotherapy
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking Union Medical College Hospital
Pancreatic Adenocarcinoma, Homologous Recombination Deficiency
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency
The purpose of this study is to evaluate the efficacy of cisplatin based regimen to patients with advanced pancreatic cancer and homologous recombination deficiency.
- Trial name
- PTCA199-6 (NCT06095141)
- Testing
- Cisplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Tumor, Adenocarcinoma
A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma
This is a clinical research study to learn if pembrolizumab in combination with lenvatinib can help to control pancreatic ductal adenocarcinoma.
- Trial name
- NCT05273554
- Testing
- Pembrolizumab, lenvatinib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Clear Cell Renal Cell Carcinoma, Cervical Carcinoma
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX131™ in subjects with relapsed or refractory solid tumors.
- Conditions
- Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT05795595
- Testing
- CTX131
- Where
- 7 sites in United States
- Volunteers
- 19 people
- Sponsor
- CRISPR Therapeutics AG
Advanced Solid Tumors, Glioblastoma
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
Prospective, open-label, dose-ranging, uncontrolled phase I/II study of Lurbinectedin in combination with irinotecan. The study will be divided into two stages: a Phase I dose escalation stage and a Phase II expansion stage.
- Conditions
- Advanced Solid Tumors, Glioblastoma, Soft Tissue Sarcoma (Excluding GIST), Endometrial Carcinoma
- Trial name
- NCT02611024
- Testing
- Lurbinectedin, Irinotecan
- Where
- 23 sites in United States, France and 4 more
- Volunteers
- 316 people
- Sponsor
- PharmaMar
Pancreatic Neoplasms, Laparoscopic Pancreaticoduodenectomy
Open Versus Total Laparoscopic Pancreaticoduodenectomy
The goal of this clinical trial is to learn more about Total Laparoscopic pancreaticoduodenectomy ( TLPD ) which is performed for participants with pancreatic tumors using the laparoscope.
- Conditions
- Pancreatic Neoplasms, Laparoscopic Pancreaticoduodenectomy, Whipple Operation
- Trial name
- NCT06661135
- Testing
- TLPD total laparoscopic pancreaticoduodenectomy, OPD open pancreaticoduodenectomy
- Where
- Egypt
- Volunteers
- 48 people
- Sponsor
- Cairo University
Oncologic Complications, Quality of Life
Nutrition and Pharmacological Algorithm for Oncology Patients Study
Loss of appetite is a common symptom of patients with cancer and can cause distress which impacts patients and caregivers. Patients diagnosed with head/neck, lung or pancreatic cancer will be recruited for this study to decrease…
- Conditions
- Oncologic Complications, Quality of Life, Nutrition Poor, Head and Neck Cancer
- Trial name
- NCT04155008
- Testing
- Dexamethasone, Dronabinol, Mirtazapine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Montefiore Medical Center
Pancreatic Neuroendocrine Neoplasm, Sorafenib
A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNET
The incidence rate of pancreatic neuroendocrine neoplasms (pNENs) is increasing year by year. According to the statistical results of the SEER (Surveillance, Epidemiology, and End Results) database, the incidence rate of pNENs…
- Conditions
- Pancreatic Neuroendocrine Neoplasm, Sorafenib, Gefitinib
- Trial name
- NCT06592989
- Testing
- sorafenib, gefitinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Pancreatic Cancer
Comparing Parenteral Nutrition vs Best Supportive Nutritional Care in Patients With Pancreatic Cancer
A randomised multicentre clinical phase IIIb trial for patients suffering from pancreatic adenocarcinoma receiving defined second or higher line chemotherapy and additionally parenteral nutrition (study arm A) or best supportive…
- Trial name
- PANUSCO (NCT01362582)
- Testing
- SMOF Kabiven
- Where
- 4 sites in Germany
- Volunteers
- 32 people
- Sponsor
- National Center for Tumor Diseases, Heidelberg
Resectable Pancreatic Carcinoma
Preoperative Chemoradiotherapy With Gemcitabine for Resectable Pancreatic Carcinoma
This phase II study is to evaluate the efficacy of preoperative chemoradiotherapy with gemcitabine (400mg/m2, weekly) for resectable pancreatic cancer.
- Trial name
- NCT01333124
- Testing
- chemoradiotherapy with Gemcitabine, Radiation: chemoradiotherapy with Gemcitabine
- Where
- South Korea
- Volunteers
- 23 people
- Sponsor
- National Cancer Center, Korea
Pancreatic Cancer
Randomized Trial of Restrictive Versus Liberal Perioperative Fluid Management for Patients Undergoing Pancreatic Resection
The purpose of this study is to help us learn what the best amount of fluid is that patients should receive during pancreas surgery.
- Trial name
- NCT01058746
- Testing
- restrictive perioperative fluid management, Liberal perioperative fluid management
- Where
- United States
- Volunteers
- 331 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.